BiotechTV - News Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
Oct 2, 2026
Markus Warmuth, CEO of Monte Rosa Therapeutics and a specialist in protein degradation and inflammatory disease, discusses MRT-8102, a molecular glue targeting the NEK7-NLRP3 inflammasome. Topics include cardiovascular inflammation biomarkers, translational evidence, safety and patient selection, and the company’s expanding pipeline across immunology, oncology, and CDK2-Cyclin E1 programs.
AI Snips
Chapters
Transcript
Episode notes
Basel’s Ten-Minute Biotech Ecosystem
- Basel’s compact ecosystem makes collaboration unusually convenient for Monte Rosa Therapeutics.
- Markus Warmuth can walk five minutes to Novartis, reach Roche by tram, and even swim the Rhine home.
Cellular Selectivity Makes Molecular Glues Safer
- Pharma’s confidence in molecular glues increasingly rests on demonstrated cellular selectivity and improving safety packages.
- Monte Rosa tests degradation against thousands of proteins, rather than relying on narrowly chosen biochemical assays.
NEK7 Degradation Targets Multiple Inflammatory Diseases
- MRT8102 degrades NEK7, a scaffolding protein within the NEK7-NLRP3 inflammasome complex that drives inflammatory cascades.
- The same mechanism could address atherosclerotic disease, gout, hidradenitis suppurativa, and other crystal-triggered inflammation.